Financial insights of CAI

MyFinsight

For the quarter ending 2025-09-30, CAI made $406,037K in revenue. $24,325K in net income. Net profit margin of 5.99%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30
Cost of services-Pharma Research And Development Services	-	2,392
Total revenue	216,833	181,398
Cost of services-Molecular Profiling Services	66,980	65,321
Selling and marketing expense	41,267	42,260
General and administrative expense (see note 10)	51,973	64,367
Research and development expense	21,624	25,047
Total costs and operating expenses	184,191	199,387
Income (loss) from operations	32,642	-17,989
Interest income	7,360	1,618
Interest expense	13,507	19,208
Changes in fair value of financial instruments	-2,081	-17,870
Other income (expense), net	-89	-18,341
Total other expense, net	-8,317	-53,801
Income (loss) before income taxes and provision for income taxes	24,325	-71,790
Provision for income taxes	0	0
Net income (loss)	24,325	-71,790
Deemed dividend from series d redeemable convertible preferred stock (see note 6)	0	384,436
Adjustments of redeemable convertible preferred stock to redemption value	0	60,971
Net income (loss) attributable to common shareholders basic	24,325	-517,197
Net income (loss) attributable to common shareholders diluted	24,325	-517,197

Basic (in dollars per share)	0.09	-7.97
Basic (in shares)	282,099,073	64,918,988
Diluted (in dollars per share)	0.08	-7.97
Diluted (in shares)	297,211,838	64,918,988